Approved

Buserelin: Uses, Evidence, and Clinical Trial Data

Molecular formulaC60H86N16O13
Molecular weight1239.4 g/mol
Registered trials43
PubChem CID50225

Buserelin is a synthetic hormone agent used in settings where suppressing natural sex hormone production is the clinical goal. Patients and clinicians researching it often want to know what conditions it addresses and what trial evidence supports its use.

Key takeaways

  • Buserelin has an approved drug label and has reached the highest level of clinical development (max phase 4).
  • It is registered across 43 clinical trials, spanning oncology and reproductive medicine.
  • Trial data in the sample include completed and active Phase 3 studies in prostate cancer and ovarian stimulation.
  • No FAERS adverse event reports were available in this dataset to summarize.
  • Its PubChem entry (CID 50225) describes a large peptide structure, consistent with its hormone-agonist class.

What the evidence shows

Buserelin is linked to 43 registered clinical trials. Among the sampled studies, a completed Phase 3 trial evaluated buserelin alongside hormone therapy, radiation, and an androgen synthesis inhibitor in patients with high-risk prostate cancer. A related Phase 3 trial, still active and not recruiting, is testing treatment intensity tailored to genetic risk scores in the same patient population. A separate completed Phase 3 trial examined buserelin within dual ovarian stimulation protocols for patients with poor ovarian response, reflecting its use in reproductive medicine alongside its oncology applications.

Reported side effects

No adverse event report data were available for buserelin in this dataset, so a summary of reported reactions cannot be provided here.

FAQ

What is buserelin used for?
Trial data show buserelin studied in high-risk prostate cancer, often combined with hormone therapy and radiation, and in reproductive medicine as part of ovarian stimulation protocols. It has an approved label and has reached the most advanced stage of clinical development.
How many clinical trials have studied buserelin?
Buserelin is registered across 43 clinical trials. These span oncology research, including prostate cancer treatment, and fertility-related studies such as ovarian stimulation.
Is buserelin still being studied in prostate cancer?
Yes. One sampled trial testing treatment intensity based on genetic risk scores in high-risk prostate cancer patients is listed as active and not recruiting, meaning enrollment has closed but the study is ongoing.
Are there known side effects of buserelin?
This dataset did not include adverse event report data for buserelin, so no side effect pattern can be summarized here. Anyone considering buserelin should review its full prescribing information for safety details.
What type of compound is buserelin?
Buserelin is a large peptide compound, identified in PubChem under CID 50225. It belongs to a hormone-agonist drug class based on its clinical development history.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: PubChem CID 50225 ClinicalTrials.gov (43 registered trials) NCT01546987 NCT04513717 NCT06199960

Updated 2026-11-14